Streetbeat News

Analyst Ratings

APA

Mizuho analyst Nitin Kumar maintains an Underperform rating on APA (NASDAQ:APA) and raises the price target from $37 to $39.

Portfolio Pulse from richadhand@benzinga.com

July 14, 2023 | 1:39 pm

TSX:FM

Raymond James analyst Farooq Hamed has downgraded First Quantum Minerals from Outperform to Market Perform.

Portfolio Pulse from richadhand@benzinga.com

July 14, 2023 | 1:28 pm

CRBU

PFE

Caribou Biosciences has raised $125 million through an upsized underwritten public offering of 19.2 million shares at $6.50 per share. This comes a week after Pfizer invested $25 million in the company. Caribou also reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 1:28 pm

TSX:ERO

Raymond James analyst Brian MacArthur has downgraded Ero Copper from Outperform to Market Perform.

Portfolio Pulse from richadhand@benzinga.com

July 14, 2023 | 1:27 pm

NPWR

Janney Montgomery Scott has initiated coverage on NET Power (NYSE:NPWR) with a Buy rating and a price target of $35.

Portfolio Pulse from richadhand@benzinga.com

July 14, 2023 | 1:25 pm

GIS

Argus Research analyst David Coleman has upgraded General Mills (NYSE:GIS) from Hold to Buy and set a price target of $90.

Portfolio Pulse from richadhand@benzinga.com

July 14, 2023 | 1:23 pm

KTRA

Maxim Group analyst Jason McCarthy has upgraded Kintara Therapeutics (NASDAQ:KTRA) from Hold to Buy and announced a $14 price target.

Portfolio Pulse from richadhand@benzinga.com

July 14, 2023 | 1:22 pm

THRX

Theseus Pharmaceuticals Inc (NASDAQ:THRX) has decided to terminate the development of THE-630 for gastrointestinal stromal tumors (GIST) due to dose-limiting toxicities. The company will discontinue enrollment in the ongoing phase 1/2 study. The decision was made after observing hand-foot skin reactions in patients. The company is now prioritizing THE-349 for EGFR mutant non-small cell lung cancer and announced a new program targeting KIT for patients with early-line GIST. Following the news, THRX shares are down 65.50%.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 1:19 pm

C

SPY

Citigroup's CFO has stated that their base case is for a mild recession, but also noted that the U.S. economy has proven to be quite resilient.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:15 pm

META

TSLA

The rivalry between Tesla CEO Elon Musk and Meta Platforms CEO Mark Zuckerberg is intensifying, with both billionaires competing in terms of employee salaries and social media platforms. Musk's Twitter and Zuckerberg's Threads are in direct competition, with Musk threatening a lawsuit over alleged intellectual property theft. Average annual pay at Tesla ranges from $50,000 to $260,000, while at Meta, salaries range from $100,000 to over $400,000. Musk also offered stock grants to Twitter employees at a $20 billion valuation.

Portfolio Pulse from Adam Eckert

July 14, 2023 | 1:10 pm